505 related articles for article (PubMed ID: 36175881)
1. Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom.
Brunetti VC; St-Jean A; Dell'Aniello S; Fisher A; Yu OHY; Bugden SC; Daigle JM; Hu N; Alessi-Severini S; Shah BR; Ronksley PE; Lix LM; Ernst P; Filion KB;
BMC Endocr Disord; 2022 Sep; 22(1):241. PubMed ID: 36175881
[TBL] [Abstract][Full Text] [Related]
2. Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide-1 Receptor Agonists, and Sodium-Glucose Cotransporter-2 Inhibitors and COVID-19 Outcomes.
Foresta A; Ojeda-Fernandez L; Macaluso G; Roncaglioni MC; Tettamanti M; Fortino I; Leoni O; Genovese S; Baviera M
Clin Ther; 2023 Apr; 45(4):e115-e126. PubMed ID: 36933975
[TBL] [Abstract][Full Text] [Related]
3. Sodium-glucose co-transporter-2 inhibitors and the risk of venous thromboembolism: A nationwide population-based study and meta-analysis.
Tsai HR; Lin YJ; Yeh JI; Huang YC; Liu PP; Peng CC; Hsu JY; Lee YC; Loh CH; Lin SM; Huang HK
Diabetes Metab Res Rev; 2024 Feb; 40(2):e3739. PubMed ID: 37862117
[TBL] [Abstract][Full Text] [Related]
4. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Incident Atrial Fibrillation in Older Adults With Type 2 Diabetes.
Zhuo M; D'Andrea E; Paik JM; Wexler DJ; Everett BM; Glynn RJ; Kim SC; Patorno E
JAMA Netw Open; 2022 Oct; 5(10):e2235995. PubMed ID: 36219443
[TBL] [Abstract][Full Text] [Related]
5. A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disease and type 2 diabetes.
Fu EL; Mastrorilli J; Bykov K; Wexler DJ; Cervone A; Lin KJ; Patorno E; Paik JM
Kidney Int; 2024 Mar; 105(3):618-628. PubMed ID: 38101515
[TBL] [Abstract][Full Text] [Related]
6. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes.
Zhuo M; Hawley CE; Paik JM; Bessette LG; Wexler DJ; Kim DH; Tong AY; Kim SC; Patorno E
JAMA Netw Open; 2021 Oct; 4(10):e2130762. PubMed ID: 34705014
[TBL] [Abstract][Full Text] [Related]
7. Two years with GIOIA 'Effects of gliflozins and gliptins on markers of cardiovascular damage in type 2 diabetes': A prospective, multicentre, quasi-experimental study on sodium-glucose cotransporter 2 and dipeptidyl peptidase-4 inhibitors in diabetes clinical practice.
Longo M; Caruso P; Scappaticcio L; Maiorino MI; Bellastella G; Capuano A; Esposito K; Giugliano D
Diabetes Obes Metab; 2024 Apr; 26(4):1492-1501. PubMed ID: 38234208
[TBL] [Abstract][Full Text] [Related]
8. Health care utilization and costs associated with switching from DPP-4i to GLP-1RA or SGLT2i: an observational cohort study.
Newman TV; Munshi KD; Neilson LM; Good CB; Swart ECS; Huang Y; Henderson R; Parekh N
J Manag Care Spec Pharm; 2021 Apr; 27(4):435-443. PubMed ID: 33769857
[No Abstract] [Full Text] [Related]
9. Influence of early use of sodium-glucose transport protein 2 inhibitors, glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on the legacy effect of hyperglycemia.
Deng S; Zhao H; Chai S; Sun Y; Shen P; Lin H; Zhan S
Front Endocrinol (Lausanne); 2024; 15():1369908. PubMed ID: 38803473
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of SGLT-2i and GLP-1RA Therapy Among Patients With Type 2 Diabetes and Varying NAFLD Status.
Bea S; Jeong HE; Filion KB; Yu OH; Cho YM; Lee BH; Chang Y; Byrne CD; Shin JY
JAMA Netw Open; 2023 Dec; 6(12):e2349856. PubMed ID: 38153732
[TBL] [Abstract][Full Text] [Related]
11. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
[TBL] [Abstract][Full Text] [Related]
12. Comparable COVID-19 outcomes with current use of GLP-1 receptor agonists, DPP-4 inhibitors or SGLT-2 inhibitors among patients with diabetes who tested positive for SARS-CoV-2.
Israelsen SB; Pottegård A; Sandholdt H; Madsbad S; Thomsen RW; Benfield T
Diabetes Obes Metab; 2021 Jun; 23(6):1397-1401. PubMed ID: 33502076
[TBL] [Abstract][Full Text] [Related]
13. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study.
Kim YG; Han SJ; Kim DJ; Lee KW; Kim HJ
Cardiovasc Diabetol; 2018 Jun; 17(1):91. PubMed ID: 29935543
[TBL] [Abstract][Full Text] [Related]
14. The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study.
Paul SK; Bhatt DL; Montvida O
Eur Heart J; 2021 May; 42(18):1728-1738. PubMed ID: 33289789
[TBL] [Abstract][Full Text] [Related]
15. Examining the risk of depression or self-harm associated with incretin-based therapies used to manage hyperglycaemia in patients with type 2 diabetes: a cohort study using the UK Clinical Practice Research Datalink.
Gamble JM; Chibrikov E; Midodzi WK; Twells LK; Majumdar SR
BMJ Open; 2018 Oct; 8(10):e023830. PubMed ID: 30297350
[TBL] [Abstract][Full Text] [Related]
16. The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis.
de Wit HM; Te Groen M; Rovers MM; Tack CJ
Br J Clin Pharmacol; 2016 Jul; 82(1):301-14. PubMed ID: 26935973
[TBL] [Abstract][Full Text] [Related]
17. SGLT-2 inhibitors and the risk of hospitalization for community-acquired pneumonia: A population-based cohort study.
Brunetti VC; Reynier P; Azoulay L; Yu OHY; Ernst P; Platt RW; Filion KB
Pharmacoepidemiol Drug Saf; 2021 Jun; 30(6):740-748. PubMed ID: 33428309
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019.
McCoy RG; Van Houten HK; Deng Y; Mandic PK; Ross JS; Montori VM; Shah ND
JAMA Netw Open; 2021 Feb; 4(2):e2035792. PubMed ID: 33523188
[TBL] [Abstract][Full Text] [Related]
19. Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).
Tan X; Divino V; Amamoo J; Xie L; Coyle KB; Gamble CL; Guevarra M; Paprocki Y; King AA
Clin Drug Investig; 2024 Apr; 44(4):271-284. PubMed ID: 38507188
[TBL] [Abstract][Full Text] [Related]
20. Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in real-world use: systematic review and meta-analysis of observational studies.
Hidayat K; Du X; Shi BM
Osteoporos Int; 2019 Oct; 30(10):1923-1940. PubMed ID: 31134305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]